An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

References

• David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256.
   PubMed Web of Science ®Google Scholar
• Gamble E, Qiu Y, Wang D, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J. 2006;27(2):293–299. doi:10.1183/09031936.06.00027705
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40(3):724–741. doi:10.1183/09031936.00213711
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold? Semin Respir Crit Care Med. 2015;36(4):508–522. doi:10.1055/s-0035-1555611
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Annibale R, Russo F, Cazzola M. Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Rev Clin Pharmacol. 2021;14(8):1015–1027. doi:10.1080/17512433.2021.1925537
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Is it time to look beyond bronchodilators and corticosteroids in treating COPD? Future Drug Discov. 2021;3(2):FDD61. doi:10.4155/fdd-2021-0001
   Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. doi:10.1016/j.coph.2020.11.003
   PubMed Web of Science ®Google Scholar
• Gea J. The future of biological therapies in COPD. Arch Bronconeumol. 2018;54(4):185–186. doi:10.1016/j.arbr.2018.02.013
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Rogliani P, Calzetta L, Cazzola M. Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease. Drugs. 2016;76(13):1257–1270. doi:10.1007/s40265-016-0625-9
   PubMed Web of Science ®Google Scholar
• Lange P, Ahmed E, Lahmar ZM, Martinez FJ, Bourdin A. Natural history and mechanisms of COPD. Respirology. 2021;26(4):298–321. doi:10.1111/resp.14007
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2):1900651. doi:10.1183/13993003.00651-2019
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou J, Diao X, Wang S. Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2019;13:1753466619866096. doi:10.1177/1753466619866096
   Web of Science ®Google Scholar
• Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004;170(5):492–498. doi:10.1164/rccm.200404-511OC
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. TNF-a inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther. 2010;23(2):121–128. doi:10.1016/j.pupt.2009.10.007
   PubMed Web of Science ®Google Scholar
• Zhu NL, Li C, Huang HH, et al. TNF-alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells. Gene. 2007;393(1–2):70–80. doi:10.1016/j.gene.2007.01.016
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, Kauffman HF, Ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–469. doi:10.1164/rccm.200501-147OC
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934. doi:10.1164/rccm.200607-995OC
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1):234–238. doi:10.1016/j.pupt.2007.03.003
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Maltais F, et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142–148. doi:10.1136/thoraxjnl-2012-202432
   PubMed Web of Science ®Google Scholar
• Dejager L, Dendoncker K, Eggermont M, et al. Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol. 2015;8(6):1212–1225. doi:10.1038/mi.2015.12
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Karaman M, Bagriyanik HA, et al. Comparison of TNF antagonism by etanercept and dexamethasone on airway epithelium and remodeling in an experimental model of asthma. Int Immunopharmacol. 2013;17(3):768–773. doi:10.1016/j.intimp.2013.08.021
   PubMed Web of Science ®Google Scholar
• Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2003;284(4):L566–77. doi:10.1152/ajplung.00233.2002
   PubMed Web of Science ®Google Scholar
• Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926–934. doi:10.1378/chest.126.3.926
   PubMed Web of Science ®Google Scholar
• Adage T, Del Bene F, Fiorentini F, et al. PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation. Cytokine. 2015;76(2):433–441. doi:10.1016/j.cyto.2015.08.006
   PubMed Web of Science ®Google Scholar
• Bilusic M, Heery CR, Collins JM, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019;7(1):240. doi:10.1186/s40425-019-0706-x
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;31:15–27. doi:10.1016/j.pupt.2015.01.005
   PubMed Web of Science ®Google Scholar
• Fu JJ, McDonald VM, Baines KJ, Gibson PG. Airway IL-1β and systemic inflammation as predictors of future exacerbation risk in asthma and COPD. Chest. 2015;148(3):618–629. doi:10.1378/chest.14-2337
   PubMed Web of Science ®Google Scholar
• Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis. 2010;73(2):86–87.
   PubMedGoogle Scholar
• Rogliani P, Matera MG, Puxeddu E, et al. Emerging biological therapies for treating chronic obstructive pulmonary disease: a pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018;50:28–37. doi:10.1016/j.pupt.2018.03.004
   PubMed Web of Science ®Google Scholar
• Osei ET, Brandsma CA, Timens W, Heijink IH, Hackett TL. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. Eur Respir J. 2020;55(2):1900563. doi:10.1183/13993003.00563-2019
   PubMed Web of Science ®Google Scholar
• Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(Suppl 5):S322–8. doi:10.1513/AnnalsATS.201403-118AW
   PubMedGoogle Scholar
• Le Rouzic O, Pichavant M, Frealle E, Guillon A, Si-Tahar M, Gosset P. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J. 2017;50(4):1602434. doi:10.1183/13993003.02434-2016
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol. 2009;157(2):316–324. doi:10.1111/j.1365-2249.2009.03965.x
   PubMed Web of Science ®Google Scholar
• Shibabaw T. Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy. J Inflamm Res. 2020;13:673–680. doi:10.2147/JIR.S278335
   PubMed Web of Science ®Google Scholar
• Liu M, Wu K, Lin J, et al. Emerging biological functions of IL-17A: a new target in chronic obstructive pulmonary disease? Front. Pharmacol. 2021;12:695957.
   Web of Science ®Google Scholar
• Ritzmann F, Beisswenger C. Preclinical studies and the function of IL-17 cytokines in COPD. Ann Anat. 2021;237:151729. doi:10.1016/j.aanat.2021.151729
   PubMed Web of Science ®Google Scholar
• Eich A, Urban V, Jutel M, et al. A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease. COPD. 2017;14(5):476–483. doi:10.1080/15412555.2017.1335697
   PubMedGoogle Scholar
• Seys SF, Lokwani R, Simpson JL, Bullens DMA. New insights in neutrophilic asthma. Curr Opin Pulm Med. 2019;25(1):113–120. doi:10.1097/MCP.0000000000000543
   PubMed Web of Science ®Google Scholar
• Kolls JK, Kanaly ST, Ramsay AJ. Interleukin-17: an emerging role in lung inflammation. Am J Respir Cell Mol Biol. 2003;28(1):9–11. doi:10.1165/rcmb.2002-0255PS
   PubMed Web of Science ®Google Scholar
• Khokhlovich E, Grant S, Kazani S, et al. The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients [abstract]. Eur Respir J. 2017;50(suppl61):OA2897.
   Google Scholar
• Shastri MD, Chong WC, Dua K, et al. Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators. Inflammopharmacology. 2021;29(1):15–33.
   Web of Science ®Google Scholar
• Christenson SA, van den Berge M, Faiz A, et al. An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. J Clin Invest. 2019;129(1):169–181. doi:10.1172/JCI121087
   PubMed Web of Science ®Google Scholar
• Baker JR, Donnelly LE. Leukocyte Function in COPD: clinical Relevance and Potential for Drug Therapy. Int J Chron Obstruct Pulmon Dis. 2021;16:2227–2242. doi:10.2147/COPD.S266394
   PubMed Web of Science ®Google Scholar
• Kirsten A, Watz H, Pedersen F, et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers. Eur Respir J. 2013;41(1):239–241. doi:10.1183/09031936.00123612
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136(3):531–545. doi:10.1016/j.jaci.2015.05.052
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Puxeddu E, Cazzola M. Airflow obstruction: is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:3007–3013. doi:10.2147/COPD.S54927
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193–198. doi:10.1136/thx.2004.032516
   PubMed Web of Science ®Google Scholar
• Nagasaki T, Matsumoto H, Nakaji H, et al. Smoking attenuates the age-related decrease in IgE levels and maintains eosinophilic inflammation. Clin Exp Allergy. 2013;43(6):608–615.
   Web of Science ®Google Scholar
• Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016;138(4):977–983. doi:10.1016/j.jaci.2016.04.028
   PubMed Web of Science ®Google Scholar
• Van Rossem I, Vandevoorde J, Hanon S, Deridder S, Vanderhelst E. The stability of blood eosinophils in stable chronic obstructive pulmonary disease: a retrospective study in Belgian primary care. BMC Pulm Med. 2020;20(1):200. doi:10.1186/s12890-020-01234-3
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16(2):186–200. doi:10.1097/ACI.0000000000000251
   PubMed Web of Science ®Google Scholar
• Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667–670. doi:10.1111/resp.12475
   PubMed Web of Science ®Google Scholar
• Caramori G, Adcock IM, Di Stefano A, Chung KF. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397–412.
   PubMed Web of Science ®Google Scholar
• Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045–1051. doi:10.2147/COPD.S155306
   PubMed Web of Science ®Google Scholar
• Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;12(12):CD013432.
   PubMed Web of Science ®Google Scholar
• Yousuf A, Ibrahim W, Greening NJ, Brightling CE. T2 biologics for chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2019;7(5):1405–1416. doi:10.1016/j.jaip.2019.01.036
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755–1770. doi:10.2147/COPD.S294333
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8(2):158–170. doi:10.1016/S2213-2600(19)30338-8
   PubMed Web of Science ®Google Scholar
• Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295. doi:10.1172/JCI85664
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901. doi:10.1016/S2213-2600(14)70187-0
   PubMed Web of Science ®Google Scholar
• Saco TV, Pepper A, Casale TB. Uses of biologics in allergic diseases: what to choose and when. Ann Allergy Asthma Immunol. 2018;120(4):357–366. doi:10.1016/j.anai.2018.02.029
   PubMed Web of Science ®Google Scholar
• Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J. 2019;53(5):1801291. doi:10.1183/13993003.01291-2018
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129–155.
   PubMedGoogle Scholar
• Borowski A, Vetter T, Kuepper M, et al. Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain. Cytokine. 2013;61(2):546–555. doi:10.1016/j.cyto.2012.10.025
   PubMed Web of Science ®Google Scholar
• Zhang K, Shan L, Rahman MS, Unruh H, Halayko AJ, Gounni AS. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L375–82. doi:10.1152/ajplung.00045.2007
   PubMed Web of Science ®Google Scholar
• Redhu NS, Gounni AS. Function and mechanisms of TSLP/TSLPR complex in asthma and COPD. Clin Exp Allergy. 2012;42(7):994–1005. doi:10.1111/j.1365-2222.2011.03919.x
   PubMed Web of Science ®Google Scholar
• Calvén J, Yudina Y, Hallgren O, et al. Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases. J Innate Immun. 2012;4(1):86–99. doi:10.1159/000329131
   PubMed Web of Science ®Google Scholar
• Elder MJ, Webster SJ, Williams DL, Gaston JS, Goodall JC. TSLP production by dendritic cells is modulated by IL-1β and components of the endoplasmic reticulum stress response. Eur J Immunol. 2016;46(2):455–463. doi:10.1002/eji.201545537
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, Cazzola M. TSLP Inhibitors for asthma: current status and future prospects. Drugs. 2020;80(5):449–458. doi:10.1007/s40265-020-01273-4
   PubMed Web of Science ®Google Scholar
• Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692. doi:10.3389/fimmu.2019.00692
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31–37. doi:10.1016/j.coi.2014.09.004
   PubMed Web of Science ®Google Scholar
• Donovan C, Hansbro PM. IL-33 in chronic respiratory disease: from preclinical to clinical studies. ACS Pharmacol Transl Sci. 2019;3(1):56–62. doi:10.1021/acsptsci.9b00099
   PubMedGoogle Scholar
• Xia J, Zhao J, Shang J, et al. IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L619–27. doi:10.1152/ajplung.00305.2014
   PubMed Web of Science ®Google Scholar
• Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(21)00167-3
   Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, Rogliani P. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635–646. doi:10.1080/17425247.2020.1739021
   PubMed Web of Science ®Google Scholar
• Maillet A, Guilleminault L, Lemarié E, et al. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res. 2011;28(9):2147–2156. doi:10.1007/s11095-011-0442-5
   PubMed Web of Science ®Google Scholar
• Respaud R, Marchand D, Parent C, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs. 2014;6(5):1347–1355. doi:10.4161/mabs.29938
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: pharmacokinetic profiles. Respir Med. 2019;153:3–13. doi:10.1016/j.rmed.2019.05.005
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, Matera MG. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21(4):345–355. doi:10.1007/s40291-017-0266-z
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8:1533. doi:10.12688/f1000research.19811.1
   Google Scholar
• Nucera F, Lo Bello F, Shen SS, et al. Role of Atypical chemokines and chemokine receptors pathways in the pathogenesis of COPD. Curr Med Chem. 2021;28(13):2577–2653. doi:10.2174/0929867327999200819145327
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469. doi:10.1183/09031936.00099306
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Hanania NA. Management of asthma COPD overlap. Ann Allergy Asthma Immunol. 2019;123(4):335–344. doi:10.1016/j.anai.2019.07.021
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Matera MG, Facciolo F, Rogliani P. Targeting IL-5 pathway against airway hyperresponsiveness: a comparison between benralizumab and mepolizumab. Br J Pharmacol. 2020;177(20):4750–4765. doi:10.1111/bph.15240
   PubMed Web of Science ®Google Scholar
• Manson ML, Säfholm J, James A, et al. IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol. 2020;145(3):808–817. doi:10.1016/j.jaci.2019.10.037
   PubMed Web of Science ®Google Scholar
• Siafakas N. Monoclonal antibodies for chronic obstructive pulmonary disease. Pulmonology. 2020;26(2):61–62. doi:10.1016/j.pulmoe.2019.11.002
   Web of Science ®Google Scholar
• McDonald VM, Fingleton J, Agusti A. participants of the Treatable Traits Down Under International Workshop; Treatable Traits Down Under International Workshop participants: Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable Traits Down Under International Workshop report. Eur Respir J. 2019;53(5):1802058.
   PubMed Web of Science ®Google Scholar
• Bel EH, Ten Brinke A. New anti-eosinophil drugs for asthma and COPD: targeting the Trait! Chest. 2017;152(6):1276–1282. doi:10.1016/j.chest.2017.05.019
   PubMed Web of Science ®Google Scholar